Prelude Capital Management’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History

Prelude Capital Management’s Portfolio INFI Stock Details INFI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-157,247	Closed	-$426K	–	2256
2018 Q3	$426K	Buy	157,247 +71,835	+84%	+$149K	0.02%	568
2018 Q2	$163K	Buy	+85,412	New	+$173K	0.01%	794
2017 Q3	–	Sell	-2,400	Closed	-$4K	–	1967
2017 Q2	$4K	Sell	2,400 -51,300	-96%	-$98.9K	﹤0.01%	1486
2017 Q1	$173K	Sell	53,700 -800	-1%	-$1.97K	0.02%	616
2016 Q4	$74K	Buy	54,500 +40,900	+301%	+$53.4K	0.01%	929
2016 Q3	$21K	Sell	13,600 -4,700	-26%	-$7.22K	﹤0.01%	1339
2016 Q2	$24K	Buy	18,300 +16,007	+698%	+$74.9K	﹤0.01%	1225
2016 Q1	$12K	Sell	2,293 -2,830	-55%	-$17.3K	﹤0.01%	1161
2015 Q4	$40K	Buy	+5,123	New	+$44.1K	0.01%	1086
2015 Q3	–	Sell	-5,400	Closed	-$59K	–	1874
2015 Q2	$59K	Buy	5,400 +2,200	+69%	+$28.2K	0.01%	1102
2015 Q1	$45K	Sell	3,200 -7,800	-71%	-$119K	0.01%	1351
2014 Q4	$186K	Buy	+11,000	New	+$160K	0.03%	678
2014 Q1	–	Sell	-500	Closed	-$6.71K	–	2158
2013 Q4	$7K	Sell	500 -500	-50%	-$7.06K	﹤0.01%	1536
2013 Q3	$17K	Sell	1,000 -9,048	-90%	-$173K	﹤0.01%	1231
2013 Q2	$163K	Buy	+10,048	New	+$311K	0.04%	489

Other funds holding INFI

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

OAM

Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return

Prelude Capital Management's INFI Position: Q4 2018 in Review

Prelude Capital Management sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q4 2018, closing a stake of 157,247 shares — an estimated $426K sold.

Prelude Capital Management first reported a position in INFI in Q2 2013 and held it in 15 quarters. The position peaked at $426K in Q3 2018. 64 funds tracked by Wall St. Rank hold INFI as of Q4 2018.

Prelude Capital Management reported no remaining Infinity Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
Prelude Capital Management sold 157,247 Infinity Pharmaceuticals, Inc. shares in Q4 2018, an estimated $426K.
Prelude Capital Management first reported a position in Infinity Pharmaceuticals, Inc. in Q2 2013 and held it in 15 quarters.
Prelude Capital Management's Infinity Pharmaceuticals, Inc. position peaked at $426K in Q3 2018.
64 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q4 2018.

Based on Prelude Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.